Dabigatran, known generically as dupliyumab, is currently available for the treatment of moderate-to-severe atopic dermatitis in patients 12 years of age and older. Dupliyuzumab is indicated for patients 12 years of age and older with moderate-to-severe atopic dermatitis that is not well controlled by topical medications or for which topical medications are not recommended, and does not require injections of dupliyuzumab in patients with mild disease that is controlled by topical or oral medications. Dupliyuzumab is effective in improving the symptoms of rash and itching in patients with atopic dermatitis by inhibiting the inflammatory response mainly through blocking inflammatory channels. The common adverse reactions of this drug include injection site reaction, conjunctivitis, oral herpes, etc. It is contraindicated for those who are allergic to the ingredients of this drug, and should be used with caution in pregnant and lactating women. If you suffer from atopic dermatitis, it is recommended to have your condition evaluated by a professional physician before formulating a suitable treatment plan, and the drug must be used in a standardized manner under the guidance of a physician.